Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Case report: severe cytomegalovirus primary infection in an immunocompetent adult with disseminated intravascular coagulation treated with valganciclovir.

Müller NF, Schampera M, Jahn G, Malek NP, Berg CP, Hamprecht K.

BMC Infect Dis. 2016 Jan 19;16:19. doi: 10.1186/s12879-016-1343-3.

2.

Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial.

Shiffman ML, Cheinquer H, Berg CP, Berg T, de Figueiredo-Mendes C, Dore GJ, Ferraz ML, Mendes-Corrêa MC, Lima MP, Parise ER, Rios AM, Reuter T, Sanyal AJ, Shafran SD, Hohmann M, Tatsch F, Bakalos G, Zeuzem S.

Hepatol Int. 2014 Oct;8(4):517-26. doi: 10.1007/s12072-014-9555-3. Epub 2014 Jul 24.

PMID:
26202757
3.

Epidemiology and Genotyping of Patients with Chronic Hepatitis B: Genotype Shifting Observed in Patients from Central Europe.

Bissinger AL, Fehrle C, Werner CR, Lauer UM, Malek NP, Berg CP.

Pol J Microbiol. 2015;64(1):15-21.

4.

First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort.

Werner CR, Franz C, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP.

Virol J. 2015 Mar 3;12:37. doi: 10.1186/s12985-015-0261-0.

5.

[Sometimes a liver can cause you headaches].

Müller NF, Lauer UM, Horger M, Malek NP, Berg CP.

Dtsch Med Wochenschr. 2014 Jun;139(25-26):1352. doi: 10.1055/s-0034-1370149. Epub 2014 Jun 25. German.

6.

Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.

Werner CR, Franz C, Egetemeyr DP, Janke-Maier P, Malek NP, Lauer UM, Berg CP.

J Viral Hepat. 2014 May;21(5):333-40. doi: 10.1111/jvh.12145. Epub 2013 Aug 5.

PMID:
24716636
7.

Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy.

Werner CR, Egetemeyr DP, Nadalin S, Königsrainer A, Malek NP, Lauer UM, Berg CP.

Z Gastroenterol. 2014 Jan;52(1):27-34. doi: 10.1055/s-0033-1356345. Epub 2014 Jan 13.

PMID:
24420796
8.

Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results.

Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP.

PLoS One. 2013 Nov 12;8(11):e80528. doi: 10.1371/journal.pone.0080528. eCollection 2013.

9.

Is the HDV seroprevalence in patients admitted to a university hospital representative for all HBV carriers in Germany?

Bissinger AL, Berg CP.

Infection. 2013 Oct;41(5):1031-2. doi: 10.1007/s15010-013-0433-z. Epub 2013 Feb 24. No abstract available.

PMID:
23435721
10.
11.

Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.

Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP.

Liver Transpl. 2012 Dec;18(12):1464-70. doi: 10.1002/lt.23542.

12.

[69-year-old man with painless jaundice and known liver cysts].

Berg CP, Gregor M, Lauer UM.

Dtsch Med Wochenschr. 2010 Dec;135(49):2459-60. doi: 10.1055/s-0030-1269417. Epub 2010 Nov 30. German. No abstract available.

PMID:
21120786
13.

Autoantibodies to muscarinic acetylcholine receptors found in patients with primary biliary cirrhosis.

Berg CP, Blume K, Lauber K, Gregor M, Berg PA, Wesselborg S, Stein GM.

BMC Gastroenterol. 2010 Oct 16;10:120. doi: 10.1186/1471-230X-10-120.

14.

Hepatitis C virus core protein induces apoptosis-like caspase independent cell death.

Berg CP, Schlosser SF, Neukirchen DK, Papadakis C, Gregor M, Wesselborg S, Stein GM.

Virol J. 2009 Dec 1;6:213. doi: 10.1186/1743-422X-6-213.

15.

Mycoplasma antigens as a possible trigger for the induction of antimitochondrial antibodies in primary biliary cirrhosis.

Berg CP, Kannan TR, Klein R, Gregor M, Baseman JB, Wesselborg S, Lauber K, Stein GM.

Liver Int. 2009 Jul;29(6):797-809. doi: 10.1111/j.1478-3231.2008.01942.x.

PMID:
19638108
16.

Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.

Horger M, Lauer UM, Schraml C, Berg CP, Koppenhöfer U, Claussen CD, Gregor M, Bitzer M.

BMC Cancer. 2009 Jun 28;9:208. doi: 10.1186/1471-2407-9-208.

17.

Apoptosis-associated antigens recognized by autoantibodies in patients with the autoimmune liver disease primary biliary cirrhosis.

Berg CP, Stein GM, Keppeler H, Gregor M, Wesselborg S, Lauber K.

Apoptosis. 2008 Jan;13(1):63-75.

PMID:
18060504
18.

Choledochoduodenal fistula after liver transplantation.

Werner CR, Lauer UM, Berg CP, Kaiser S, Ludescher B, Luz O, Ladurner R, Gregor M, Graepler F.

Liver Transpl. 2007 Nov;13(11):1608-10. No abstract available.

19.

Demonstration of PDC-E1 subunits as major antigens in the complement-fixing fraction M4 and re-evaluation of PDC-E1-specific antibodies in PBC patients.

Berg CP, Stein GM, Klein R, Pascu M, Berg T, Kammer W, Priemer M, Nordheim A, Schulze-Osthoff K, Gregor M, Wesselborg S, Berg PA.

Liver Int. 2006 Sep;26(7):846-55.

PMID:
16911468
20.

Ribavirin and alpha interferon enhance death receptor-mediated apoptosis and caspase activation in human hepatoma cells.

Schlosser SF, Schuler M, Berg CP, Lauber K, Schulze-Osthoff K, Schmahl FW, Wesselborg S.

Antimicrob Agents Chemother. 2003 Jun;47(6):1912-21.

Items per page

Supplemental Content

Write to the Help Desk